Amia Capital’s Alnylam Pharmaceuticals ALNY Stock Holding History

Amia Capital’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-6,937	Closed	-$1.01M	–	8
2020 Q3	$1.01M	Sell	6,937 -2,467	-26%	-$351K	1.17%	13
2020 Q2	$1.39M	Sell	9,404 -4,542	-33%	-$612K	1.14%	12
2020 Q1	$1.52M	Sell	13,946 -3,957	-22%	-$457K	1.35%	11
2019 Q4	$2.06M	Buy	+17,903	New	+$1.78M	0.6%	17

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Amia Capital's ALNY Position: Q4 2020 in Review

Amia Capital sold out of Alnylam Pharmaceuticals (ALNY) in Q4 2020, closing a stake of 6,937 shares — an estimated $1.01M sold.

Amia Capital first reported a position in ALNY in Q4 2019 and held it in 4 quarters. The position peaked at $2.06M in Q4 2019. 376 funds tracked by Wall St. Rank hold ALNY as of Q4 2020.

Amia Capital reported no remaining Alnylam Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
Amia Capital sold 6,937 Alnylam Pharmaceuticals shares in Q4 2020, an estimated $1.01M.
Amia Capital first reported a position in Alnylam Pharmaceuticals in Q4 2019 and held it in 4 quarters.
Amia Capital's Alnylam Pharmaceuticals position peaked at $2.06M in Q4 2019.
376 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2020.

Based on Amia Capital's 13F filing for Q4 2020, filed 11 Feb 2021.